|
Valoración de DCF de Qualigen Therapeutics, Inc. (QLGN)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Qualigen Therapeutics, Inc. (QLGN) Bundle
Ya sea que sea un inversor o analista, esta calculadora DCF (QLGN) es su herramienta esencial para una valoración precisa. Con datos reales de Qualigen Therapeutics, Inc., puede ajustar los pronósticos y observar instantáneamente los resultados.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.6 | 4.3 | 5.7 | 5.0 | 5.2 | 5.2 | 5.2 | 5.3 | 5.3 | 5.3 |
| Revenue Growth, % | 0 | -22.52 | 31.29 | -11.85 | 4.44 | 0.33855 | 0.33855 | 0.33855 | 0.33855 | 0.33855 |
| EBITDA | -10.0 | -11.2 | -22.7 | -13.8 | -11.3 | -5.2 | -5.2 | -5.3 | -5.3 | -5.3 |
| EBITDA, % | -180.31 | -259.27 | -400.85 | -277.74 | -217.12 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .1 | .1 | .3 | .0 | .0 | .1 | .1 | .1 | .1 | .1 |
| Depreciation, % | 2 | 3.22 | 5.7 | 0.2441 | 0.08636334 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 |
| EBIT | -10.1 | -11.3 | -23.0 | -13.9 | -11.3 | -5.2 | -5.2 | -5.3 | -5.3 | -5.3 |
| EBIT, % | -182.32 | -262.49 | -406.55 | -277.98 | -217.2 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | .2 | 24.0 | 17.5 | 7.0 | .4 | 3.2 | 3.3 | 3.3 | 3.3 | 3.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .7 | .6 | .8 | .0 | .0 | .4 | .4 | .4 | .4 | .4 |
| Account Receivables, % | 12.73 | 14.3 | 14.55 | 0 | 0 | 8.31 | 8.31 | 8.31 | 8.31 | 8.31 |
| Inventories | .7 | 1.0 | 1.1 | 1.6 | .0 | .9 | .9 | .9 | .9 | .9 |
| Inventories, % | 11.88 | 22.14 | 18.68 | 31.83 | 0 | 16.9 | 16.9 | 16.9 | 16.9 | 16.9 |
| Accounts Payable | .9 | .5 | .9 | .6 | 2.2 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Accounts Payable, % | 15.82 | 11.63 | 15.68 | 12.43 | 42.71 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 |
| Capital Expenditure | -.2 | -.2 | -.1 | -.3 | .0 | -.2 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -3.5 | -4.88 | -2.5 | -6.4 | 0 | -3.46 | -3.46 | -3.46 | -3.46 | -3.46 |
| Tax Rate, % | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 |
| EBITAT | -10.2 | -11.3 | -23.0 | -13.7 | -12.2 | -5.2 | -5.2 | -5.2 | -5.3 | -5.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.7 | -12.0 | -22.7 | -14.0 | -9.0 | -7.8 | -5.3 | -5.3 | -5.3 | -5.3 |
| WACC, % | 11.73 | 11.73 | 11.73 | 11.65 | 11.73 | 11.71 | 11.71 | 11.71 | 11.71 | 11.71 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -21.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5 | |||||||||
| Terminal Value | -56 | |||||||||
| Present Terminal Value | -32 | |||||||||
| Enterprise Value | -54 | |||||||||
| Net Debt | 1 | |||||||||
| Equity Value | -55 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | -10.78 |
What You Will Get
- Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Qualigen Therapeutics, Inc.’s (QLGN) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, market penetration, and R&D expenditures.
- Instant Valuation Metrics: Quickly computes intrinsic value, NPV, and additional financial outputs.
- High-Precision Accuracy: Relies on Qualigen Therapeutics' actual financial data for realistic valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and assess outcomes with ease.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Qualigen Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Qualigen Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Qualigen Therapeutics, Inc. (QLGN)?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your specific analysis needs.
- Real-Time Feedback: Instantly view changes to Qualigen’s valuation as you tweak inputs.
- Preloaded Data: Comes with Qualigen’s current financial metrics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for sound decision-making.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for assessing investment opportunities in the biotech sector.
- Corporate Development Teams: Evaluate valuation scenarios to inform strategic decisions and partnerships.
- Consultants and Advisors: Deliver precise valuation insights for Qualigen Therapeutics, Inc. (QLGN) to clients.
- Students and Educators: Utilize current data to practice and teach financial modeling in the biotech industry.
- Biotech Enthusiasts: Gain insights into how companies like Qualigen Therapeutics, Inc. (QLGN) are valued within the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Qualigen Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Qualigen Therapeutics, Inc. (QLGN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.